Age-specific seroprevalence of hepatitis A in Antananarivo (Madagascar).
BACKGROUND
Hepatitis A virus (HAV) is an enteric, viral, infectious disease endemic in many developing countries such as Madagascar. Infection is often subclinical or asymptomatic in children; however, symptomatic acute infections become more common with increasing age. In some developing countries, improvements in living conditions have led to changes in the epidemiological pattern of HAV infection. There are very few reports on the prevalence of HAV in Madagascar. This study was to determine the seroprevalence of hepatitis A virus antibodies in relation to age in the city of Antananarivo, Madagascar.


METHODS
Serum samples collected in 2004 during a cross-sectional survey of individuals aged between two and 24 years from Antananarivo were tested for anti-HAV antibody using a commercial enzyme immunoassay kit. Subjects were investigated using a standardized social and medical history questionnaire.


RESULTS
926 subjects were enrolled including 406 males and 520 females. There were 251 children under 10 years old and 675 subjects between 10 and 24 years old. Of the 926 serum samples tested, 854 (92.2%) were positive for anti-HAV antibodies. The number of seropositive samples was similar for males and females. The overall seroprevalence was 83.7% (210/251) for children under 10 years old and 95.5% (644/675) for subjects aged between 10 and 24 years (p < 0.001).


CONCLUSIONS
Despite improvements in sanitary conditions and hygiene over the last few years, the prevalence of HAV in Antananarivo is high. Only children under five years old remain susceptible to HAV infection. Immunization against HAV is not needed at the present time in the Madagascan population, but should be recommended for travellers.
Unité d'Epidémiologie, Institut Pasteur de Madagascar, BP 1274, Antananarivo 101, Madagascar. rvmalala@pasteur.mg
Vaomalala
V
Raharimanga
Jean-François
JF
Carod
Charles-Emile
CE
Ramarokoto
Jean-Baptiste
JB
Chrétien
Fanjasoa
F
Rakotomanana
Antoine
A
Talarmin
Vincent
V
Richard
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000914:Antibodies, Viral / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D006506:Hepatitis A / Q000453:epidemiology / Q000276:immunology* / Q000821:virology; D035922:Hepatitis A Antibodies / Q000097:blood*; D006801:Humans; D008270:Madagascar / Q000453:epidemiology; D008297:Male; D015995:Prevalence; D018570:Risk Assessment; D016036:Seroepidemiologic Studies; D011795:Surveys and Questionnaires
D000914:Antibodies, Viral; D035922:Hepatitis A Antibodies